Immunotherapy in food allergy: towards new strategies

Sakura Sato,¹ Noriyuki Yanagida,² Kiyotake Ogura,¹ Tomoyuki Asaumi,² Yu Okada,² Yumi Koike,² Katsuhito Iikura,² Akinori Syukuya² and Motohiro Ebisawa¹

Summary

Allergen avoidance is the standard treatment for managing food allergies. Complete avoidance is difficult, and accidental exposure often occurs. Immunotherapy is a significant focus for treating food allergies, and oral immunotherapy (OIT) appears to be particularly effective in inducing desensitization. The majority of patients who receive OIT show increased threshold doses of their food allergen. The efficacy of OIT is different among food antigen, and milk OIT is relatively difficult to achieve tolerance. OIT may induce mild to moderate symptoms during the therapy, widespread acceptance of OIT for long-term therapy is unclear. Recently, novel immunotherapies for food allergies, such as sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT) and using an anti-IgE monoclonal antibody (omalizumab), have been assessed. In addition, a combination of OIT with omalizumab, which was found to increase the threshold doses of the offending foods without producing adverse reactions, may be effective and useful in the treatment of food allergies. These treatments have been used only in research settings; further studies in large numbers of patients are needed to demonstrate their long-term safety and benefits in clinical practice. (Asian Pac J Allergy Immunol 2014;32:195-202)

Keywords: food allergy, immunotherapy, oral, sublingual, tolerance, desensitization

Introduction

Food allergies have become ever more prevalent in recent decades. The current management for food allergy includes identifying the offending foods and avoiding them.¹ Because accidental exposure to food allergens often occurs,² patients must be prepared to treat an allergic reaction. The difficulty in avoiding the foods to which they are allergic and the potential for an unexpected sudden and life-threatening reaction³ diminish the quality of life both for the patient and his family.

The concept of immunotherapy is not new, but it has not been practical. Subcutaneous immunotherapy (SCIT) for peanut allergy was rejected owing to the high rate of severe adverse reactions.⁴ Recently, oral immunotherapy (OIT) has been investigated as a therapeutic approach for food allergy,⁵⁻¹² and numerous clinical trials, including randomized controlled trials, have been completed. More recently, sublingual immunotherapy (SLIT) and epicutaneous immunotherapy (EPIT) with an anti-IgE monoclonal antibody (omalizumab) have been examined. These treatments increased patient threshold doses of food and decreased the incidence of adverse reactions, and they may be useful to treat food allergies. In this paper, we review the clinical trials of OIT as well as recent advances in other immunotherapies for managing food allergies.

Oral immunotherapy

Immunologic responses with OIT

Although the mechanism of OIT has not yet been clearly demonstrated, it has been shown to induce desensitization and tolerance (Figure 1),¹³ compared to baseline values, at 12 and 18 months (Figure 2).⁷ Antigen-specific IgE levels in subjects receiving OIT tended to increase early, but decreased subsequently. A significant increase in specific IgG levels occurred after the patients had been on OIT for 3 months, but the levels gradually returned to baseline by 33 months. On the other hand, specific IgG4 levels increased initially and remained elevated until the end of the study. OIT is most commonly associated with a reduction in antigen-
specific IgE level and an increase in antigen-specific IgG4 level, although some studies have reported no change in antigen-specific IgE levels during treatment with OIT.\(^5\,6\,14\,15\) Since these changes in antigen-specific IgE, IgG, and IgG4 levels were seen only in subjects receiving OIT, these immunologic responses seem to be allergen-specific.\(^6\) More recently, Vickery et al reported that these immunologic responses were associated with changes in epitope binding patterns, indicating that OIT induces shifts in the antibody repertoire.\(^17\)

Modulation of immunologic cells is thought to be a predominant mechanism for immunotherapy (Figure 1).\(^13\) Skin prick test (SPT) reactivity showed a significant decrease several months after a course of treatment and it remained diminished throughout the three-year follow-up.\(^7\) Additionally, some early studies reported that OIT induced a reduction in basophil count, which was evident four to six months after treatment.\(^7\,18\) Burks et al. also reported that basophil activation decreased with OIT administration and that the reduced basophil activation was associated with desensitization.\(^15\) Moreover, OIT reduced Th2 and increased regulatory T cells (Treg) counts. Blumchen et al. reported that peanut OIT was associated with reduced peanut-induced Th2 cytokine production (IL-4 and IL-5).\(^8\) In contrast, Jones et al. reported increased IL-5 and TNF-\(\alpha\) production in patients who underwent peanut OIT.\(^7\)

**Efficacy of OIT**

Many studies have shown that the majority of subjects receiving OIT were desensitized and that continuous allergen exposure increased the threshold of clinical reactivity to food\(^5\,6\,9\,11\,12\,15\) (Table 1). On the other hand, whether or not the tolerance induced by OIT resembles natural tolerance that has spontaneously developed in food allergy patients is unknown.

Several controlled studies of patients with peanut, milk, and egg allergies have shown that OIT increases the threshold of reactivity to the causative food. Varshney et al. reported a study of peanut OIT in 28 subjects with peanut allergy.\(^19\) After therapy, 16 (93\%) of the 19 subjects who received active treatment were able to ingest 4.0 gram of peanut protein, whereas the control subjects reacted to doses less than 0.28 gram. In 2014, Anagnostou et al. reported the results of a phase 2 randomized controlled trial of peanut OIT,\(^20\) which showed that OIT induced desensitization in most subjects with a peanut allergy of any severity, a clinically meaningful increase in the peanut threshold.

Equal numbers of milk OIT trials and peanut OIT trials have been published. Table 1 shows the results of just the randomized controlled trials.
These studies found significant differences between patients who underwent OIT and those who maintained an elimination diet.\textsuperscript{5,11,14} The success rate for desensitization ranged from 36 to 67%. The lowest rate reported was in a study in which severely milk-allergic subjects with a history of anaphylaxis to milk and milk-specific IgE levels above 85 kUA/L were enrolled.\textsuperscript{11}

Fewer egg OIT trials than peanut or milk OIT trials have been described. In 2012, Burks et al. reported a double-blind, randomized, placebo-controlled study of egg OIT in 55 children with egg allergy.\textsuperscript{15} After 10 months of therapy, not one of the children who received a placebo and 55% of those who received OIT passed an oral food challenge (OFC) and were thus considered to be desensitized.

![Figure 2. Changes of peanut-specific Immunoglobulins levels during peanut OIT](image-url)

Table 1. Efficacy of OIT for food

<table>
<thead>
<tr>
<th>Food</th>
<th>Study (published year)</th>
<th>Subjects</th>
<th>Duration/ Target dose</th>
<th>Clinical outcomes 1</th>
<th>Clinical outcomes 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peanut</td>
<td>Varshney et al. (2011)</td>
<td>2-10 years OIT: 19 Control: 9</td>
<td>Duration of OIT: 48 weeks Target dose: 4000 mg</td>
<td>OIT: threshold dose ↑ Control: threshold dose was lower than OIT group</td>
<td>Desensitization: 84% Dropout: 16%</td>
</tr>
<tr>
<td></td>
<td>Anagnostou et al. (2014)</td>
<td>7-16 years OIT: 39 Control: 46</td>
<td>Duration of OIT: 24 weeks Target dose: 800 mg</td>
<td>OIT: threshold dose ↑ Control: no changed</td>
<td>Desensitization: 62% Dropout: 2%</td>
</tr>
<tr>
<td>Milk</td>
<td>Longo et al. (2008)</td>
<td>5-17 years OIT: 30 Control: 30</td>
<td>Duration of OIT: 1 year Target dose: 150 mL</td>
<td>OIT: threshold dose ↑ Control: no changed</td>
<td>Desensitization: 36% Dropout: 10%</td>
</tr>
<tr>
<td></td>
<td>Skripak et al. (2008)</td>
<td>6-17 years OIT: 13 Control: 7</td>
<td>Duration of OIT: 13 weeks Target dose: 15 mL</td>
<td>OIT: threshold dose ↑ Control: no changed</td>
<td>Desensitization: 46% Dropout: 8%</td>
</tr>
<tr>
<td></td>
<td>Pajno et al. (2010)</td>
<td>4-13 years OIT: 15 Control: 15</td>
<td>Duration of OIT: 48 weeks Target dose: 200 mL</td>
<td>OIT: threshold dose ↑ Control: no changed</td>
<td>Desensitization: 67% Dropout: 10%</td>
</tr>
</tbody>
</table>
Twenty-two months after the therapy began, 75% of children in the OIT group had been desensitized. Furthermore, after two months of complete egg avoidance, 28% (11 of 40 children) of the OIT group passed the OFC at 24 months, and their unresponsiveness to the allergen was considered to be sustained. At 30 months and 36 months, all children who had passed the OFC at 24 months were consuming egg without any problem.¹⁵

These studies mostly excluded patients with food-induced anaphylaxis. Since 2008, in National Sagamihara Hospital, we have been using OIT in patients with egg, cow’s milk, and wheat anaphylaxis.²¹ We have enrolled over 250 patients with food anaphylaxis, defined by a double-blind, placebo-controlled, food challenge (DBPCFC). Our OIT protocol consists of three steps: 1) initial build-up phase in the hospital, 2) slow build-up phase at home, and 3) maintenance phase. Finally, while the patients were on the maintenance dose for 3 months or more, they discontinued OIT for 2 weeks and returned for a final OFC, to determine their tolerance for the offending food. After two years, 92.2% of patients on egg OIT (daily intake of 1 heated whole egg), 75.0% of the milk OIT patients (daily intake of 200 mL milk), and 100% of wheat OIT patients (daily intake of 5.2 g of wheat powder) had been successfully desensitized (Figure 3). Moreover, the patients who had passed OFC at the end of the therapy included 61.5% of those on egg OIT, 27.1% of those on milk OIT, and 83.3% of those on wheat OIT; these patients might achieve clinical tolerance. The efficacy of OIT seems to differ among food antigens, in cases of severe food allergy. It is comparatively difficult to achieve clinical tolerance with milk OIT.

Safety of OIT

Patient safety is critical for the commercial success of OIT. Although adverse reactions were frequently reported, most were localized. Some systemic reactions requiring adrenaline injection have been reported.⁵,⁶,⁹,¹¹,¹₂,¹₅ (Table 2). Importantly, the systemic reactions occurred not only during the dose escalation phase, but also during home administration.²²,²³ The overall risk associated with the allergen exposure varies with the characteristics of the population from which the subjects are enrolled. In OIT for severe milk allergy, the incidence of adverse reactions was higher than that observed in other studies.¹¹ In our trial of OIT with patients who could develop food anaphylaxis, the patients receiving milk OIT showed the highest incidence of moderate and severe reactions, followed by those who with egg and those with wheat allergies.²⁴ Further trials to investigate the safety of OIT in patients with severe food-induced anaphylaxis are needed.

A systematic review of cow’s milk OIT compared to an elimination diet demonstrated the association of OIT with a greater risk of allergic
reactions that require adrenaline injection or systemic corticosteroid. 25 However, because the study covered a small number of subjects, the greater risk of OIT over an elimination diet remains uncertain.

**Tolerability of OIT**

The studies cited above demonstrated that OIT for food allergy is effective in increasing the amount of food that treated patients tolerate by 50% or more. 5, 7, 9, 14, 15 However, the long-term effects of OIT are still uncertain.

In fact, it is not yet clear whether the tolerance of those who passed the OFC without receiving therapy can be considered permanent or whether their desensitization is transient. Tolerance is defined as a permanent loss of reactivity correlated with the ability to ingest the offending food in the absence of ongoing therapy without incurring symptoms. 13 On the other hand, desensitization—defined as “a change in the threshold dose of food allergen necessary to cause allergic reactions”—can be either short term or prolonged by ongoing therapy. 26 Little data address the question whether OIT for food allergy induces permanent tolerance or whether the effects represent transient desensitization. Many patients lose desensitization after suspending OIT. 63 In a recent study by Keet et al., 10 6 of the 15 subjects, who passed a full milk challenge after 60 weeks of maintenance, lost desensitization after 1 and 6 weeks off the therapy. Desensitization is quickly lost when OIT therapy is interrupted. Although it seems likely that maintaining a state of desensitization requires ongoing exposure, we do not know how often patients should ingest foods they were previously allergic to. Previous studies suggested that desensitization induced by OIT does not quickly lead to tolerance. It is possible that a longer period of daily maintenance treatment may be required for most patients to develop tolerance or, at least, similar to the maintenance period for SCIT for inhaled allergens.

**Clinical trials of other immunotherapies**

**Sublingual immunotherapy**

SLIT methods involve placing quite small immunotherapy doses under the tongue. The method has been shown effective in the treatment of allergic
rhinitis. Two randomized, controlled trials of SLIT for peanut have been published. Fleisher et al. reported SLIT with peanut in a multi-center, double-blind, placebo-controlled trial in which 40 subjects of median age 15 years old were enrolled. Maintenance doses ranged from 165 to 1386 mg of peanut protein. At week 44 after starting the therapy, fourteen (70%) of 20 subjects who received active treatment had increased their threshold doses of the allergen, but none of the subjects passed the 5 gram of peanut OFC. Additionally, adverse reactions, mostly mild, did not require oral antihistamine administration.

Keet et al. directly compared the efficacy of SLIT and OIT for milk. The study enrolled 30 randomized subjects with milk allergy who received SLIT alone or SLIT followed by OIT. After an initial SLIT escalation, the subjects were randomized, one group would continue SLIT only and the other would begin OIT at two different maintenance doses. Sixty weeks later, only one subject in the SLIT group passed the 8 gram of milk OFC, compared to six in the lower-dose OIT group and eight in the higher-dose OIT groups. Systemic reactions were more common during OIT than during SLIT. Patients with peanut allergy treated with either peanut OIT or SLIT also experienced greater efficacy associated with OIT than with SLIT. These results showed that OIT is more effective than SLIT alone in achieving desensitization. Combination therapy of SLIT and OIT might benefit from the safety of SLIT and the potential for tolerating ever greater doses of food with OIT.

**Epicutaneous immunotherapy**

Epicutaneous immunotherapy (EPIT) may be a new approach for food allergy. EPIT, which involves the application of an allergen-loaded patch on intact skin, was shown to desensitize milk-allergic patients. Subjects in the active treatment group could tolerate higher doses of milk in OFC during follow-up visits than subjects in the placebo group. Adverse effects consisted mostly of local

<table>
<thead>
<tr>
<th>Table 3. Clinical trials of novel immunotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Sublingual immunotherapy (SLIT)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>SLIT + OIT</td>
</tr>
<tr>
<td>Epicutaneous immunotherapy (EPIT)</td>
</tr>
<tr>
<td>OIT + Omalizumab</td>
</tr>
</tbody>
</table>
skin reactions and included no severe systemic reaction. This pilot study suggests that EPIT is safe and well-tolerated; epicutaneous administration may be an effective option for delivering immunotherapy.

The anti-IgE monoclonal antibody

The anti-IgE monoclonal antibody (omalizumab), a recombinant humanized monoclonal IgE-blocking antibody, works by decreasing or preventing the allergic response triggered by IgE molecules. Adjunct administration of recombinant monoclonal anti-IgE therapy may be a promising strategy to improve the safety profile associated with OIT. 32,33

Nadeau et al. reported a pilot study of omalizumab treatment combined with milk OIT. 33 After nine weeks of pretreatment with omalizumab alone, a course of OIT with omalizumab was given, followed by a period of maintenance OIT without omalizumab and, finally, a DBPCFC at week 24. Nine of 10 subjects achieved the target dose and passed the DBPCFC. The incidence of adverse reactions, which were mostly mild, was 1.8%. Only one subject developed rhinitis and a generalized urticaria; he responded to adrenaline when tested under a DBPCFC protocol. This result suggests that use of recombinant monoclonal anti-IgE therapy would be effective in reducing severe adverse reactions during the escalation phases of OIT.

Conclusion

OIT can increase the threshold dose to a food allergen and lead to desensitization. Although OIT appears to be an effective new therapy for food allergies, even without tolerance, the evidence for its efficacy and safety in long-term therapy is sparse. Moreover, some novel immunotherapies and routes of administration might be effective for food allergies. SLIT and EPIT show that patients can increase their threshold doses to a food allergen without suffering severe symptoms. Adding anti-IgE monoclonal antibody to OIT therapy reduces the incidence of the symptoms seen during OIT therapy alone. These new therapies have not yet been fully assessed for efficacy; the data available come from only a few studies, which were based on small sample sizes. Further studies are needed before these therapies can be offered to patients in clinical practice.

Acknowledgements

We are grateful for the collaboration of Ms. Miho Hasegawa, Ms. Chizuko Sugizaki, Noriko Hayashi, and all of our co-workers.

We are supported by the Health and Labor Sciences Research Grants of the Research on Allergic Disease and Immunology from the Ministry of Health, Labour and Welfare (Japan).

References


